753004-00-1

Upstream product

• 753003-99-5 C₆₇H₈₂O₁₇ 

Downstream Products

• 1599463-45-2 diosgenyl 2,3,4-tri-O-acetyl-α-L-rhamnopyranosyl-(1→2)-[2,3,4-tri-O-benzoyl-α-D-lyxopyranosyl-(1→3)]-4,6-di-O-benzylidene-β-D-galactopyranoside 
• 1599463-46-3 diosgenyl 2,3,4-tri-O-acetyl-α-L-rhamnopyranosyl-(1→2)-[2,3,4-tri-O-benzoyl-β-D-ribopyranosyl-(1→3)]-4,6-di-O-benzylidene-β-D-galactopyranoside 
• 1599463-47-4 diosgenyl 2,3,4-tri-O-acetyl-α-L-rhamnopyranosyl-(1→2)-[2,3,4-tri-O-benzoyl-α-L-arabinopyranosyl-(1→3)]-4,6-di-O-benzylidene-β-D-galactopyranoside 

Relevant academic research and scientific papers

Efficient synthesis and antitumor activities of indioside e analogs

An efficient synthesis of seven analogs of a naturally occurring saponin, indioside E, is described. The synthesis used a 3,4,6-O-protected D-galactopyranosyl thioglycoside as the key intermediate to enable regioselective glycosylation and one-pot multistep reactions. Antitumor activities of the synthetic saponins against a human hepatocellular carcinoma cell line BEL-7402 and a human breast adenocarcinoma cell line MCF-7 were evaluated by means of the CCK-8 assay. Analogs carrying trisaccharides with the D-xylopyranose in indioside E substituted with a D-ribopyranose and an L-arabinopyranose or with its diosgenin aglycon replaced with tigogenin exhibited similar antitumor activities as indioside E, but not other analogs.